Introduction: Subtype classification of lung adenocarcinoma (LUAD) divides different survivals and therapeutic vulnerabilities; however, little is known about the disease's underlying molecular mechanism. This study sought to determine the genetic and immune profiles of histologic subtypes and identify the evidence for adjuvant immunotherapy.
Methods:
We performed an integrated analysis of multidimensional data from a discovery set consisting of cohorts of The Cancer Genome Atlas and the Broad Institute data set from the LUAD public database and a validation set from the Guangdong Lung Cancer Institute. Immunohistochemical staining was carried out to determine the expression of the proteins programmed cell death 1 ligand (PD-L1) and CD8.
Results: Patients with solid predominant LUAD showed poor disease-free survival and a high frequency of relapse/ metastasis compared with those with the nonsolid subtype of LUAD. The solid subtype tended to occur more frequently in those with a history of smoking. Solid predominant LUAD exclusively showed increased expression of PD-L1 and a high proportion of dual positive PD-L1-and tumor-infiltrating lymphocytes. Meanwhile, a notable increase in the tumor mutation burden and higher frequency of GC>TA transversions were specifically identified in tumors of the solid subtype. Furthermore, the solid subtype of tumor displayed an active cytotoxic immune signature and increased incidence of genetic mutations related to immunogenicity.
Conclusion:
Solid predominant LUAD was identified as a subtype with adaptive immune resistance, higher cytotoxic activity, and enhanced immunogenicity. These findings suggest that patients with solid predominant LUAD may represent a potential selective group that will benefit from adjuvant programmed cell death 1 blockade immunotherapy.
Introduction
For patients with stage II to IIIA NSCLC, adjuvant chemotherapy is recommended as the standard of care. However, adjuvant chemotherapy has been reported to result in only a 4% improvement in the 5-year survival of these patients. 1 Meanwhile, this benefit was found to be partly counteracted by the toxicity of the treatment and decreased patient quality of life. Moreover, the phase III study Eastern Cooperative Oncology Group 1505 recently demonstrated no improvement in disease-free survival (DFS) and overall survival (OS) with the addition of bevacizumab to chemotherapy in completely resected stage IB to IIIA NSCLC. 2 However, these unsatisfactory results may be partly due to the limitation of all-comer strategies for adjuvant therapy. Therefore, it is necessary to distinguish the population that would benefit most from the therapy from the allcomer population in the adjuvant setting.
Immunotherapy has been recognized as an effective approach against minimal tumor burden and small deposits of tumor cells (TCs) that are accessible by the circulating immune cells (ICs). Furthermore, immunotherapy seeks to establish a repertoire of memory cells that can prevent recurrences. 3, 4 Although early vaccine trials failed to show improvements in DFS and OS postoperatively, 5, 6 immune checkpoint inhibitors have broadened the scope of adjuvant immunotherapy. 7, 8 Recent studies have shown promising benefits of programmed cell death 1 (PD-1) blockade for the treatment of advanced NSCLC. These studies illustrated a group of predictive biomarkers for the efficacy of PD-1 inhibitors, including expression of the PD-1 ligand (PD-L1), 9, 10 tumor mutational load, [11] [12] [13] presence of DNA mismatch repair deficiency, 14 and the intensity of tumorinfiltrating lymphocytes (TILs). 15 These factors are functionally interrelated and often found coordinately in individual tumor specimens. 16 Hence, this raises the question of whether some specific subgroups with two or more of these predictive factors may theoretically benefit the most from PD-1 blockade immunotherapy.
Furthermore, it has been recently proposed that the histologic pattern of lung adenocarcinoma (LUAD) influences the efficacy of adjuvant chemoradiotherapy. 17 Different prognoses and distinct driver mutation profiles 18, 19 were identified among the histologic subtypes. In particular, solid predominant tumors associated with increased TIL counts and PD-L1 expression, which have been reported as factors favorable to PD-1 blockade. 18, 20 On the basis of the aforementioned studies, we propose that the histologic subtype of LUAD may be a potential predictive factor for the efficacy of adjuvant immunotherapy. Here, we describe an integrative analysis to define the potential predictive value of the histologic subtype of LUAD for adjuvant PD-1 blockade immunotherapy.
Materials and Methods

Patient Cohort
The Cancer Genome Atlas (TCGA) and Broad Institute cohorts were defined as the discovery set. Most of the patients enrolled in the two cohorts had early-stage LUADs. A total of 194 patients with LUADs with confirmed histologic subtypes were included in the TCGA cohort, for which detailed information about the mRNA and protein expression profiles as well as gene mutation data was available. The Broad Institute cohort was obtained from the LUAD public database and contained information on 146 LUAD and matched normal tissues, with detailed information about the histologic subtypes and mutation profiles. The validation set comprised 270 patients with LUAD from the Guangdong Lung Cancer Institute (GLCI) of Guangdong General Hospital with definite histologic subtypes. Among them, 85 patients had undergone whole genome sequencing (WGS) and 194 were found by immunohistochemistry (IHC) analysis to have tumors containing PD-L1 protein, with nine patients overlapped in the whole population. In addition, 214 patients with stage I to IIIA LUADs who had completed a follow-up of at least 4 years were selected for survival analysis.
A flow diagram was provided to illustrate the study design ( Supplementary Fig. 1 ). This study was approved by the institutional review board of GLCI of Guangdong General Hospital, and all patients provided specimens with written informed consent. Key variables, including molecular and clinicopathologic characteristics of LUAD samples in the discovery and validation cohorts, are provided in Supplementary Tables 1 and 2 .
Histologic Evaluation
All available hematoxylin and eosin-stained tumor slides (a mean of five slides per patient) were reviewed by two pathologists blinded to the patient clinical outcomes (Y. F. L. and L. X. Y.). Any disagreements between the pathologists during determination of the predominant subtype were resolved through consensus by using a multiheaded microscope. Tumors were classified according to the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society classification as adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma. The percentage of each histologic pattern was recorded in 5% increments. Invasive adenocarcinomas with mixed histologic patterns were classified into one of following subtypes based on the predominant growth pattern present in the tumor: lepidic, acinar, papillary, micropapillary, solid, and invasive mucinous. 21, 22 The tumors were grouped by architectural grading as low (lepidic predominant), intermediate (papillary and acinar predominant), or high (micropapillary predominant, solid predominant, and invasive mucinous adenocarcinoma). 19, 23 The histologic subtype of cases in the TCGA (http://www.nature.com/ nature/journal/v511/n7511/full/nature13385.html# supplementary-information) 24 26, 27 For each gene in the immune signature, we considered the normalized values of reads per kilobase per million mapped reads from the TCGA database. We determined an immune signature score as the average expression level of the genes comprising the signature.
The reverse phase protein array methodology and data analysis pipeline have been previously described. 25 Level 3 data were downloaded directly from the TCGA portal and utilized in the subsequent analyses.
Mutation Data Analysis
For the discovery set (consisting of the TCGA and Broad Institute databases), somatic mutation data (level 2) of the 194 LUADs in the TGCA cohort were retrieved from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/ findArchives.htm). To assess the mutational load, the number of mutated genes carrying at least one nonsynonymous mutation in the coding region was computed for each tumor. Somatic mutation data on the 146 LUADs in the Broad Institute cohort were retrieved from cbioPortal (http://www.cbioportal.org/study.do?cancer_study_id ¼luad_broad). The mutation spectrum for each sample was calculated as the percentage of each of six possible single-nucleotide changes (AT>CG, AT>GC, AT>TA, GC>AT, GC>CG, GC>TA) among all single-nucleotide substitutions. The validation set (GLCI data) comprised 85 patients with LUAD who underwent WGS of DNA from their tumors and matched normal blood samples in the GLCI cohort. Enriched exome libraries were sequenced on the HiSeq 2000 platform (Illumina) to more than 100Â coverage. Alignment, base quality score recalibration, and duplicate read removal were performed; germline variants were excluded; mutations were annotated; and indels were evaluated as previously described. 11, 13, 28, 29 Differences in mutations between the clinical groups were compared by using the Mann-Whitney test.
DNA polymerase epsilon, catalytic subunit gene [POLE] mutations were described previously. In brief, somatic variants were located in the exonuclease domain associated with ultramutation and a frequency of C>A transversions of 20% or more.
30,31
IHC
A total of 194 LUAD tumors in the GLCI cohort were assessed by IHC staining with antibodies against PD-L1 (clone SP142 [Spring Bioscience, Pleasanton, CA]) and CD8 (clone C8/144B [Gene Tech, Shanghai, People's Republic of China]). Serial sections from surgically resected LUAD specimens of each patient in our center were used for analysis of PD-L1, CD8, and histologic subtypes. The IHC-stained tissue sections were scored separately by two pathologists who were blinded to the clinical parameters.
The PD-L1 expression in the TCs and ICs was evaluated as previously described.
9,32,33 PD-L1 expression was evaluated on TCs and tumor-infiltrating immune cells (ICs). For TCs, the proportion of PD-L1-positive cells was estimated as the percentage of total TCs staining at any intensity. TCs typically showed membranous staining with a variably strong component of cytoplasmic staining. The immunostaining for TC was scored as follows: TC3, 50% or more; TC2, more than 5% but less than 50%; TC1, at least 1% but less than 5%; and TC0, less than 1%. For tumor-infiltrating ICs, the percentage of PD-L1-positive tumor-infiltrating ICs (which included macrophages, dendritic cells, and lymphocytes) occupying the tumor was recorded. PD-L1-positive tumor-infiltrating ICs were typically seen as variably sized aggregates toward the periphery of the tumor mass, in stromal bands dissecting the tumor mass, or as single cells scattered in stroma or within tumorinfiltrating IC aggregates. The immunostaining for IC was scored as follows: IC3, 10% or more; IC2, at least 5% but less than 10%; IC1, at least 1% but less than 5%; and IC0, less than 1% (Supplementary Fig. 2A ).
The percentages of CD8-positive lymphocytes as compared with the total amount of nucleated cells in the stromal compartments were assessed as previously described, 34 by using scoring cutoff points at 25% or 50% for each section according to the degree of cell density, with low density indicating less than 25%, intermediate density indicating at least 25% but less than 50%, and high density indicating at least 50% ( Supplementary Fig. 2B ).
Statistical Analyses
Statistical analyses were conducted using GraphPad Prism (version 7.01, GraphPad Software, La Jolla, CA) and SPSS version 22.0 (IBM Corp, Armonk, NY). Scatter dot, box, and whisker plots were created to indicate the median values and 95% confidence intervals (CIs). The Mann-Whitney U, chi-square, Fisher's exact, and KruskalWallis tests were used to analyze differences in the clinical and genomic data. Kaplan-Meier curves of DFS and OS were created and compared using the log-rank test. The Cox proportional hazards model was applied for multivariate survival analyses. All reported p values are two tailed, and for all analyses, a p value of 0.05 or lower was considered statistically significant.
Results
Prognosis and Clinical Characteristics between Solid Predominant and Nonsolid Predominant LUADs
Analysis of 214 resected stage I to IIIA LUAD cases with a follow-up of at least 4 years showed poor DFS (p ¼ 0.022) and OS (p ¼ 0.015) according to the architectural grading ( Fig. 1A and Supplementary Fig. 3A) , which is consistent with the results of previous studies. 19 We To explore why patients with the solid subtype showed a poor survival, we analyzed the clinical and molecular characteristics between the solid and nonsolid subtype in 610 LUADs from the three independent cohorts (the TCGA and Broad Institute cohorts constituting the discovery set and the GLCI cohort constituting the validation set). In these cohorts, the solid predominant histologic subtype was found to account for 21% to 30% of LUAD cases. The results demonstrated that the solid predominant subtype was more common in those who had a history of smoking and did not have an EGFR activating mutation, implying that this subtype may be prone to genomic alterations but lack of a treatable target. Meanwhile, patients with the solid subtype also manifested a higher rate of recurrence than did those with the nonsolid subtype, which is consistent with its poor prognosis ( Table 2) .
PD-L1 Is Increased in Solid Predominant LUADs
Given that solid predominant LUADs showed poor DFS and a high frequency of relapse, we hypothesized that there may exist some immune resistance mechanism in the tumor microenvironment. To verify this hypnosis, we first investigated the correlation between the histologic subtype and the expression of immune checkpoints in LUAD. A heatmap depicting the expression levels of key immune checkpoints in the six subtypes was created by using data from the TCGA database. The results revealed exclusive increased expression of PD-L1 in tumors of the solid subtype compared with in other subtypes, whereas no difference in other immune checkpoint markers was observed ( Fig. 2A) . Quantitative analysis showed significantly increased expression of PD-L1 mRNA and protein (Fig. 2B) in the solid subtype compared with in other histologic subtypes. To further confirm this result, we detected the PD-L1 protein in 194 LUAD surgical specimens by IHC. Immunostaining revealed the strongest staining for PD-L1 protein in tumors of the solid subtype compared with in the other five subtypes (Fig. 2C) . Statistical analysis revealed a remarkably high proportion of PD-L1-positive cases (PD-L1 score TC3/IC3) in the solid versus nonsolid groups (p ¼ 0.003) (Fig. 2E) .
Previous studies have classified the immune microenvironment into four groups on the basis of PD-L1 expression and TIL recruitment. 35, 36 Considering these classifications, we further determined the correlation between histologic subtype and CD8-positive TIL count. IHC analysis of the 194 LUADs showed no significant relationship between the different histologic subtypes and CD8 expression (p ¼ 0.400) (Supplementary Table 3 ). However, when combined analysis of PD-L1 and CD8, the solid subtype manifested a significantly higher proportion of dual PD-L1 (score TC3/IC3) and CD8 (!50%) positivity, whereas the nonsolid subtype showed a high percentage of dual-negative expression (p ¼ .007) (Fig. 2E) . These findings partly support our former speculation that the solid subtype shows adaptive immune resistance (PD-L1-positive/TIL positive).
Solid Predominant LUADs Show Increased TMB
We next sought to determine whether an association between the histologic subtype and tumor mutation burden (TMB) or mutation spectrum existed. First, we analyzed the TCGA and the Broad Institute databases as the discovery set. The TCGA cohort showed significantly increased mutational loads in the solid subtype (median mutation count 224) compared with in the other five subtypes (157 in the acinar subtype,70 in the lepidic subtype, 138 in the papillary subytpe, 122 in the micropapillary subtype, and 38 in the invasive mucinous subtype [Fig. 3A] ). Next, we analyzed the Broad Institute data set, which comprised 146 LUADs with detailed somatic mutation data, and confirmed that the solid subtype had significantly higher median mutational loads (solid, 300; acinar, 157; lepidic, 60; papillary, 109; micropapillary, 124; and invasive mucinous, 34 [see Fig. 3A] ). To further verify these findings, the 85 LUADs from the GLCI cohort detected by WGS were defined as the validation set. The GLCI data showed results similar to those for the discovery set, with the solid subtype displaying the highest mutational load (solid, 273; acinar, 166; lepidic, 197; and others, 155 [ Fig. 3B] ).
Solid Predominant Adenocarcinomas Present with a High Rate of Transversion
We discovered a relationship between solid subtype and smoking history. On the basis of this finding, we next investigated whether the different histologic subtypes presented with distinct mutation spectra. The transversion and transition rates were classified according to the nucleotide substitution, namely, GC>TA, GC>CG, AT>TA, AT>CG, AT>GC, and GC>AT. The Broad Institute data set showed the highest rate of transversion/transition in the solid subtype, whereas the lowest rate of transversion/ transition was seen in the lepidic subtype (Fig. 3C) . It has been previously reported that the enrichment for GC>TA transversions is a genome-wide trend for somatic variations, thus forming a sharp contrast to the trend for germline variations. 25, 37 Analysis of the association between the histologic subtypes and the frequency of GC>TA transversions in the GLCI cohort revealed (as was consistent with the former results) that patients with the solid subtype showed the highest rate of GC>TA transversions, increased mutation counts, and a higher smoking index (Fig. 3D ).
Cytotoxic Immune Signature and Genetic Mutation Profiles in Solid and Nonsolid Adenocarcinomas
A recent study demonstrated that patients with preexisting immunity, defined by high T-effector cellinterferon gamma (IFN-g)-associated cytotoxic immune signature, had improved OS with a PD-L1 inhibitor. 32 We assessed the relationship between different histologic subtypes and cytotoxic immune gene expression through analysis of the TCGA database. An integrated heatmap depicted expression levels of T-effector cell and IFN-gassociated gene signature in tumors with solid and nonsolid predominant adenocarcinoma. We identified significantly higher expression of both T-effector celland IFN-g-associated genes in the solid subtype than in the nonsolid subtype, indicating preexisting immunity within the solid predominant tumors (Fig. 4A and B) . In addition, the immune signature score (defined as a cluster of genes specific for cytotoxic activity) was also analyzed between the solid and nonsolid subtypes. The results showed a significantly higher immune signature Comparison of the combined PD-L1 and CD8 expression in the solid and nonsolid subtypes. PD-L1 expression was divided into three groups by score indicating tumor cell (TC) and immune cell (IC) expression (TC3/IC3, TC2/IC2, and TC0-1/IC0-1). CD8 expression was divided into three groups: strong (!50%), weak (25%-49%), and negative (<25%). PD-L1-positive/CD8-positive was defined as a PD-L1 score of TC3/IC3 and a CD8 score of 50% or higher. SOL, solid; LEP, lepidic; ACI, acinar; PAP, papillary; MIP, micropapillary; MUC, mucinous; PDCD1, programmed cell death 1 gene; PDCD1LG2, programmed cell death 1 ligand 2 gene; CTLA4, cytotoxic T-lymphocyte associated protein 4 gene; VTCN1, V-set domain containing T-cell activation inhibitor 1gene; BTLA, B and T lymphocyte associated gene; CD40, CD40 molecule gene; CD80, CD80 molecule gene; CD86, CD86 molecule gene; LAG, lymphocyte activating 3 gene; TIM3, T-cell immunoglobulin mucin family member 3 gene; CD28, CD28 molecule gene; HHLA2, HERV-H LTR-associating 2 gene; Seq, sequencing; RPPA, reverse phase protein array; NS, no significace. ***P < 0.001, **P < 0.01, *P < 0.05.
score in the solid subtype, implying increased immune cytotoxic activity ( Supplementary Fig. 5A and B) . We next sought to understand the genetic mutation profiles that are potentially associated with tumor immunogenicity between different pathological subtypes. The heatmap manifested a relatively higher mutation frequency of POLE that was also observed in the solid subtype with a marginal statistical difference (p ¼ 0.06). Some common mutations in LUAD, including EGFR, KRAS, tumor protein p53 gene (TP53), and serine/threonine kinase 11 gene (STK11), reported in our recent study showed a correlation with tumor antigenicity and PD-L1 expression. 29 Analysis based on two independent discovery sets (the TCGA and Broad Institute data sets) indicated an increased incidence of TP53 mutation and reduced frequency of EGFR mutation in the solid subtype compared with in the nonsolid group. Meanwhile, the validation set (GLCI cohort) supported the former findings regarding EGFR and TP53 mutation and also manifested a higher frequency of KRAS and STK11 mutation in the solid subtype ( Fig. 4A and D) .
Discussion
Since the new classification of LUAD on the basis of predominant histologic pattern was published by the International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society, several studies have explored the prognostic and predictive values of different histologic subtypes in invasive LUAD. 17, 19, 22, 38 Most of these studies have supported the notion of a poor prognosis in patients with the solid and micropapillary subtypes. 17, 19, 38 The present study identified a significant relationship between the solid subtype and increased PD-L1 expression. These findings may partly explain the worse prognosis of solid LUAD stemming from an immunoresistant tumor microenvironment. Remarkably, we discovered that the solid predominant subtype was correlated with an inflamed phenotype characterized by a high proportion of PD-L1-positive/CD8-positive TILs and active cytotoxic immune profiling and that enhanced immunogenicity resulted from an increased TMB and a high frequency of transversions. This may be the first study to Histogram and heatmap displaying the integrated relationship between GC>TA transversion, mutation burden, smoking (pack-years), sex, and histologic subtypes based on analysis of the GLCI data. LUAD, lung adenocarcinoma. ***P < 0.001, **P < 0.01, *P < 0.05.
provide evidence that the solid predominant histologic subtype may be a predictive factor of adjuvant PD-1 blockade immunotherapy in resected LUAD. This selective strategy for adjuvant treatment may have important clinical implications and may, at least to some extent, change the clinical decision making regarding treatment of early-stage LUAD in the future.
Although the classification of tumors on the basis of predominant subtype is adequate to differentiate distinct survival, LUADs are frequently composed of complex heterogeneous mixtures of subtype, with a continuum from one pattern to the next (e.g., lepidic to papillary or acinar). 39 Comprehensive histologic subtyping provides a useful tool to estimate not only the predominant subtype but also minor components. It is essential to understand the impact of a solid component on the prognosis and immune profiling. Of the 167 patients in this study with nonsolid predominant subtypes, 20 (12%) displayed a solid component (from 5% to 40%). A Kaplan-Meier survival analysis examined DFS and OS in the following three groups: solid predominant versus solid component versus nonsolid. The results showed a Fig. 6A ). Interestingly, the OS of the solid component groups was closer to that for the nonsolid group (median not reached [p ¼ 0.583]) ( Supplementary Fig. 6B ). The disparity between PFS and OS may be explained by the histologic evolution that increasingly presence of solid component is responsible for early recurrence or metastasis, while the nonsolid predominant subtypes determine the whole disease evolution and overall survival. Meanwhile, PD-L1 expression was also analyzed in the aforementioned three groups. Either the solid predominant or component group showed significantly increased PD-L1 protein expression compared with that in the nonsolid group ( Supplementary  Fig. 6C ), suggesting a possibility that morphological and molecular evolutions are synchronous in LUAD.
It has been reported that the diverse of clinical outcomes in different histologic subtypes are likely due to the different genetic profile. Previous studies have shown that solid predominant LUADs are less likely to harbor EGFR mutations and more likely to harbor KRAS mutations than are other predominant subtypes. 38, 40 In our study, we confirmed these findings and showed a significantly higher incidence of TP53 and KRAS mutations and lower frequency of EGFR mutation in the solid subtype than in the nonsolid subtype. Our recently published study also demonstrated that patients with TP53 and/or KRAS mutations in advanced LUAD showed increased PD-L1 expression, high density of CD8-positive TILs, and augmented TMB, which supported a potential predictive value for PD-1 blockade immunotherapy. 29 There seems to be overlap of the predictive factors from the two studies. Actually, for advanced NSCLC, it is difficult to acquire adequate tumor samples for comprehensively evaluating histologic subtypes and small biopsy specimens are more easily lead to intratumor heterogeneous expression of PD-L1. TP53 or KRAS mutation could be routinely detected in the laboratory as a qualitative index for advanced LUAD. However, for early-stage NSCLC, it is available to obtain the overall section after surgery, and further comprehend the detailed information of histologic subtypes, whereas some testing for common biomarkers such as EGFR, KRAS, echinoderm microtubule associated protein like 4 gene (EML4)-ALK receptor tyrosine kinase gene (ALK), TP53, and PD-L1 are not mandatory after surgery in many hospitals in the People's Republic of China. Meanwhile, validating the predictive value of KRAS and TP53 is still warranted, especially in early-stage NSCLC. In this study, the solid predominant subtype of LUAD showed increased PD-L1 expression, higher cytotoxic activity, and enhanced immunogenicity, which to some extent supports the idea that the solid histologic subtype can be an optional biomarker for adjuvant immunotherapy in early stage LUAD.
There are several limitations in this study. Although we identified solid predominant LUAD with distinct immune profiles and potential therapeutic vulnerabilities, there was a lack of clinical verification of adjuvant anti-PD-1 therapy for these patients. This embarrassing lack of clinical verification is largely due to the lack of study patients from clinical trial or real-world treatment of adjuvant checkpoint blockade and a long follow-up before disease progression. Recently, there have a few ongoing adjuvant immunotherapy trials for LUAD. The phase III PACIFIC (MEDI4736), ANVIL (Nivolumab), and PEARLS (Pembrolizumab) trials are representative. Remarkably, all three trials focused on the potential beneficiary of treatment based on the subgroup analysis of PD-L1, implying that biomarker-based selective strategies for adjuvant immunotherapy might be an option. It is promising that a multivariate prediction model including histologic subtype and other potential predictive biomarkers was established by discovery and that validation patients underwent adjuvant immunotherapy. In addition, in this study, we found a relatively small proportion of solid predominant adenocarcinoma compared with that in the open source data (21% versus 29%-32%). A retrospective study from our center enrolled 1112 patients with early-stage LUAD showed only 119 tumors with solid predominant subtype (17.9%), indicating different ethnicity might attribute to the discrepancy.
In conclusion, the results of this study provided new insight into selective strategies for adjuvant PD-1 blockade immunotherapy in resected LUAD based on different histologic subtypes. The solid predominant subtype was found to correlate remarkably with increased PD-L1 expression, TMB, and mutation spectrum, supporting the use of PD-1 blockade as adjuvant therapy in this population. These findings provide significant insight for the design and interpretation of clinical trials of adjuvant therapy.
